Trademark: 79342262
Word
ILLIMIS THERAPEUTICS
Status Date
Tuesday, July 4, 2023
Registration Number
7095521
Registration Date
Tuesday, July 4, 2023
Filing Date
Thursday, March 17, 2022
Published for Opposition
Tuesday, April 18, 2023
5 Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders
42 Pharmaceutical product development; [ pharmaceutical research and development in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady/disease and dysfunction; scientific research in the field of gene therapy; ] medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; [ biotechnology research and scientific and pharmaceutical research in the antibody field; ] biological research; [ scientific research in the field of cancer disease; ] remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; [ scientific and medical research of autoimmune disease; ] development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; * pharmaceutical research and development in the field of age-related diseases, disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady, disease and dysfunction; scientific research for medical purpose in the field of gene therapy; biotechnology research; scientific research for medical purpose in the field of cancer disease; medical research of autoimmune disease; * pharmaceutical research and development in the field of inflammatory disease; pharmaceutical research and development in the field of eye disease; pharmaceutical research and development in the field of amyloidosis; * pharmaceutical * consultancy [ and information ] services relating to pharmaceutical quality control * ; providing information about pharmaceuticals research relating to pharmaceutical quality control *
The mark consists of the wording "ILLIMIS THERAPEUTICS", in stylized font, with the first letter "I", the letters "IMIS" and "THERAPEUTICS" in blue, the first letter "L" in light blue and the second letter "L" in yellow.
In the statement, " International class 42 " is corrected per the restriction dated 5/18/2023
The alphabet "Ill" was expressed with three vertical bars, which is blue, light blue, and yellow. The color part functions as a logo, and the whole including it is pronounced "illimis", the name of the applicant.
The color(s) blue, light blue, and yellow is/are claimed as a feature of the mark.
"THERAPEUTICS"
Jun 9, 2022
Sn Assigned For Sect 66a Appl From Ib
Jun 10, 2022
New Application Office Supplied Data Entered
Jun 14, 2022
Application Filing Receipt Mailed
Dec 29, 2022
Assigned To Examiner
Dec 31, 2022
Non-Final Action Written
Jan 1, 2023
Non-Final Action (Ib Refusal) Prepared For Review
Feb 27, 2023
Refusal Processed By Mpu
Feb 27, 2023
Non-Final Action Mailed - Refusal Sent To Ib
Mar 7, 2023
Teas Response To Office Action Received
Mar 7, 2023
Correspondence Received In Law Office
Mar 7, 2023
Teas/Email Correspondence Entered
Mar 11, 2023
Approved For Pub - Principal Register
Apr 5, 2023
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Mar 21, 2023
Refusal Processed By Ib
Mar 29, 2023
Notification Of Notice Of Publication E-Mailed
Apr 5, 2023
Notification Of Possible Opposition Sent To Ib
Apr 18, 2023
Published For Opposition
Apr 18, 2023
Official Gazette Publication Confirmation E-Mailed
Apr 25, 2023
Notification Processed By Ib
May 21, 2023
Limitation Of Goods Received From Ib
Jul 4, 2023
Registered-Principal Register
Jul 4, 2023
Notice Of Registration Confirmation Emailed
Oct 4, 2023
Final Disposition Notice Created, To Be Sent To Ib
Oct 14, 2023
Case Assigned To Post Registration Paralegal
Oct 14, 2023
Correction Under Section 7 - Processed
Oct 14, 2023
Case Assigned To Post Registration Paralegal
Oct 16, 2023
Limitation From The Ib Examined And Entered
Nov 21, 2023
Notice Of Updated Registration Confirmation Emailed
Jan 16, 2024
Final Disposition Processed
Feb 6, 2024
Final Decision Transaction Processed By Ib
Jan 16, 2024
Final Disposition Notice Sent To Ib
Jun 18, 2024
Partial Invalidation Of Reg Ext Protection Created
Trademark Alertz updated from USPTO on 2030-01-24
